To explain the traits of the inhabitants attended within the medical psychology programme in Major Care, in addition to to carry out a preliminary evaluation of the outcomes obtained.Potential, descriptive examine of the outcomes obtained after transient psychological intervention. The next analysis instruments had been used: PHQ-9, GAD-7, WHOQOL-BREF, and an advert hoc designed satisfaction questionnaire.A complete of 1084 sufferers had been referred to this system, and had been largely girls. Essentially the most frequent diagnoses had been anxiousness, adaptive problems, Zcodes (elements that affect the state of well being and speak to with well being companies) and depressive problems. The imply ready record time was 7.25days, and the imply variety of consultations was3.
The analyses carried out after the remedy confirmed an enchancment in all of the variables evaluated, in addition to excessive satisfaction and usefulness of the remedy.The mixing of the medical psychologist in Major Care results in an enchancment within the high quality of care of sufferers with emotional problems, facilitating an interdisciplinary bio-psycho-social strategy, and providing internationally really useful evidence-based remedies and interventions. This text presents a present (as of September 2019) record of really useful ages for confirmed terrestrial affect constructions (n = 200) and deposits (n = 46) sourced from the first literature. Excessive-precision affect ages can be utilized to (1) reconstruct and quantify the affect flux within the internal Photo voltaic System and, particularly, the Earth-Moon system, thereby putting constraints on the supply of extraterrestrial mass accreted on Earth via geologic time; (2) make the most of affect ejecta as occasion markers within the stratigraphic report and to refine bio– and magneto-stratigraphy; (3) check fashions and hypotheses of synchronous double or a number of affect occasions within the terrestrial report; (4) assess the potential hyperlink between giant impacts, mass extinctions, and diversification occasions within the biosphere; and (5) constrain the period of soften sheet crystallization in giant affect basins and the lifetime of hydrothermal programs in cooling affect craters, which can have served as habitats for microbial life on the early Earth and, presumably, Mars. Bio-based industries rely extensively on using enzymatic biocatalysts.
The worldwide marketplace for industrial enzymes, of which roughly half is used for meals functions, is estimated at $5.5 billion. Most enzymes utilized in meals manufacturing worldwide are produced by recombinant DNA methods. Manufacturing and use of meals enzymes are regulated by three fundamental our bodies: the Joint Meals and Agriculture Group of the United Nations/World Well being Group Skilled Committee on Meals Components; the European Meals Security Authority; and the U.S. Meals and Drug Administration
Addition of Isocyanide-containing Amino Acids to the Genetic Code for Protein Labeling and Activation.
Website-specific introduction of bioorthogonal handles into bio-molecules gives highly effective instruments for learning and manipulating the constructions and features of proteins. Current advances in bioorthogonal chemistry show that tetrazine-based bioorthogonal cycloaddition is a par-ticularly helpful methodology attributable to its excessive reactivity, biological selectivity, and turn-on property for fluores-cence imaging. Regardless of its broad functions in protein labeling and imaging, utilization of tetrazine-based bioorthogonal cycloaddition has been restricted thus far by the requirement of a hydrophobic strained alkene reactive moiety.
Circumventing this structural requirement, we report the site-specific incorporation of noncanonical ami-no acids (ncAAs) with a small isocyanide (or isonitrile) group into proteins in each bacterial and mammalian cells. We confirmed that, underneath physiological circumstances and within the absence of a catalyst, these isocyanide-containing ncAAs may react selectively with tetrazine molecules by way of [4+1]-cycloaddition, thus offering a flexible bioorthog-onal deal with for site-specific protein labeling and protein decaging. Considerably, these bioorthogonal reactions between isocyanides and tetrazines additionally present a novel mechanism for the activation of tetrazine-quenched fluoro-phores.
The addition of those isocyanide-containing ncAAs to the record of 20 commonly-used, naturally occurring amino acids expands our repertoire of reagents for bioorthogonal chemistry, due to this fact enabling new biological functions starting from protein labeling and imaging research to the chemical activation of proteins.
Acoustically responsive polydopamine nanodroplets: A novel theranostic agent.
Ultrasound-induced cavitation has been used as a device of enhancing extravasation and tissue penetration of anticancer brokers in tumours. Initiating cavitation in tissue nonetheless, requires excessive acoustic intensities which can be neither protected nor straightforward to realize with present medical programs. The usage of cavitation nuclei can nonetheless decrease the acoustic intensities required to provoke cavitation and the ensuing bio-effects in situ. Microbubbles, strong gas-trapping nanoparticles, and part shift nanodroplets are some examples in a rising record of proposed cavitation nuclei.
In addition to the flexibility to decrease the cavitation threshold, stability, lengthy circulation occasions, biocompatibility and biodegradability, are a number of the fascinating traits {that a} clinically relevant cavitation agent ought to possess. On this examine, we current a novel formulation of ultrasound-triggered part transition sub-micrometer sized nanodroplets (~400 nm) stabilised with a biosuitable polymer, polydopamine (PDA). PDA provides some vital advantages: (1) facile fabrication, as dopamine monomers are immediately polymerised on the nanodroplets, (2) excessive polymer biocompatibility, and (3) ease of functionalisation with different molecules similar to medication or concentrating on species.
Lambda Light Chain Antibody / Lambda Antibody |
R20179BTN-50UG |
NSJ Bioreagents |
50ug |
EUR 347.65 |
|
Description: This recombinant Human Lambda Light Chain antibody reacts to the lambda light chain of human immunoglobulins. No cross reactivity with the kappa light chain, mouse IgG, rat IgG, or goat IgG |
Lambda Light Chain Antibody / Lambda Antibody |
R20179SAF-250UG |
NSJ Bioreagents |
250ug |
EUR 832.15 |
|
Description: This recombinant Human Lambda Light Chain antibody reacts to the lambda light chain of human immunoglobulins. No cross reactivity with the kappa light chain or mouse/rat/goat IgG. |
Lambda Light Chain Antibody / Lambda Antibody |
RQ4975 |
NSJ Bioreagents |
100ul |
EUR 356.15 |
|
Description: All five immunoglobulin classes share the same basic four polypeptide chain structure of two heavy-chains and two light chains. There are five heavy chain types, and two light-chain types (Kappa and Lambda) both having a molecular weight of 22.5kDa. Any heavy-chain type can associate with either light-chain type, but on any immunoglobulin molecule both light-chains are of the same type. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V9032SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7875SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7878SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V7879SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 424.15 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3152SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3261SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: Antibodies are produced by B lymphocytes, each expressing only one class of light chain. Once set, light chain class remains fixed for the life of the B lymphocyte. In a healthy individual, the total kappa to lambda ratio is roughly 3:1 in serum (measuring intact whole antibodies) or 1:1.5 if measuring free light chains, with a highly divergent ratio indicative of neoplasm. Individual B-cells in lymphoid tissue possess either kappa or lambda light chains, but never both together. Specific rearrangement of lambda light chain of immunoglobulins can lead to loss of some protein coding genes, which does not seem to be functionally relevant (while functionally relevant miR-650 can be overexpressed). Using immunohistochemistry, it is possible to determine the relative abundance of B-cells expressing kappa and lambda light chains. If the lymph node or similar tissue is reactive, or otherwise benign, it should possess a mixture of kappa positive and lambda positive cells. If, however, one type of light chain is significantly more common than the other, the cells are likely all derived from a small clonal population, which may indicate a malignant condition, such as B-cell lymphoma. [Wiki] |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V3262SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This mAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2151SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153CF488-100T |
NSJ Bioreagents |
100 Tests |
EUR 424.15 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody / Lambda Antibody |
V2153SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: This antibody is specific to lambda light chain of immunoglobulin and shows no cross-reaction with kappa light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. In general the ratio of Kappa to Lambda is 3:1. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkin's lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
lambda light chain Antibody |
abx034778-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
lambda light chain Antibody |
abx034778-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Lambda Light chain Antibody |
43108 |
SAB |
100ul |
EUR 319 |
Lambda Light chain Antibody |
43108-100ul |
SAB |
100ul |
EUR 302.4 |
Lambda Light chain Antibody |
DF14068 |
Affbiotech |
100ul |
EUR 420 |
Lambda Light Chain Antibody |
GWB-3CD66C |
GenWay Biotech |
1 mg |
Ask for price |
Lambda Light Chain Antibody |
GWB-5BF0CA |
GenWay Biotech |
1 ml |
Ask for price |
lambda Light chain Antibody |
GWB-261355 |
GenWay Biotech |
0.2 mg |
Ask for price |
|
Lambda Light Chain Antibody |
GWB-Q00555 |
GenWay Biotech |
1 mg |
Ask for price |
lambda Light chain Antibody |
GWB-8A9A62 |
GenWay Biotech |
1 ml |
Ask for price |
Lambda Light Chain Antibody |
GWB-8C3DF1 |
GenWay Biotech |
0.2 mg |
Ask for price |
Lambda Light Chain Antibody |
GWB-97C068 |
GenWay Biotech |
1 ml |
Ask for price |
Lambda Light Chain Antibody |
GWB-9D1F37 |
GenWay Biotech |
10 ml |
Ask for price |
lambda Light chain Antibody |
GWB-A91D69 |
GenWay Biotech |
0.1 mg |
Ask for price |
lambda Light chain Antibody |
GWB-78555D |
GenWay Biotech |
10 ml |
Ask for price |
Lambda Light Chain Antibody |
GWB-FE3F89 |
GenWay Biotech |
6 ml |
Ask for price |
Lambda Light Chain Antibody |
GWB-B5882C |
GenWay Biotech |
0.5 mg |
Ask for price |
Lambda Light Chain Antibody |
GWB-E23DD9 |
GenWay Biotech |
10 ml |
Ask for price |
Lambda Light Chain Antibody |
GWB-EF36EE |
GenWay Biotech |
1 ml |
Ask for price |
lambda light chain Antibody |
abx034778-100g |
Abbexa |
100 µg |
EUR 250 |
Lambda Light Chain Antibody |
V8873-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody |
V8873-20UG |
NSJ Bioreagents |
20ug |
EUR 153.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light Chain Antibody |
V8873SAF-100UG |
NSJ Bioreagents |
100ug |
EUR 349.3 |
|
Description: This MAb is specific to lambda light chain of immunoglobulin and shows no cross-reaction with lambda light chain or any of the five heavy chains. In mammals, the two light chains in an antibody are always identical, with only one type of light chain, kappa or lambda. The ratio of Kappa to Lambda is 70:30. However, with the occurrence of multiple myeloma or other B-cell malignancies this ratio is disturbed. Antibody to the lambda light chain is reportedly useful in the identification of leukemias, plasmacytomas, and certain non-Hodgkins lymphomas. Demonstration of clonality in lymphoid infiltrates indicates that the infiltrate is malignant. |
Lambda Light chain Antibody |
MBS9415078-01mL |
MyBiosource |
0.1mL |
EUR 305 |
Lambda Light chain Antibody |
MBS9415078-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1230 |
Lambda light chain Antibody |
MBS9200064-008mL |
MyBiosource |
0.08mL |
EUR 210 |
Lambda light chain Antibody |
MBS9200064-04mL |
MyBiosource |
0.4mL |
EUR 430 |
Lambda light chain Antibody |
MBS9200064-5x04mL |
MyBiosource |
5x0.4mL |
EUR 1910 |
Lambda Light chain Antibody |
MBS9631740-1mg |
MyBiosource |
1mg |
EUR 375 |
Lambda Light chain Antibody |
MBS9631740-5x1mg |
MyBiosource |
5x1mg |
EUR 1545 |
Lambda Light chain Antibody |
MBS9629357-01mL |
MyBiosource |
0.1mL |
EUR 260 |
Lambda Light chain Antibody |
MBS9629357-02mL |
MyBiosource |
0.2mL |
EUR 305 |
Lambda Light chain Antibody |
MBS9629357-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1220 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx411151-1mg |
Abbexa |
1 mg |
EUR 661.2 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx411423-05mg |
Abbexa |
0.5 mg |
EUR 794.4 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx413204-02mg |
Abbexa |
0.2 mg |
EUR 678 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx414083-025mg |
Abbexa |
0.25 mg |
EUR 678 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415391-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415790-1mg |
Abbexa |
1 mg |
EUR 526.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415793-05mg |
Abbexa |
0.5 mg |
EUR 477.6 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415798-1mg |
Abbexa |
1 mg |
EUR 661.2 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415800-05mg |
Abbexa |
0.5 mg |
EUR 477.6 |
|
Lambda Light Chain (Lambda-IgLC) Antibody |
abx413204-200l |
Abbexa |
200 µl |
EUR 450 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx414083-200l |
Abbexa |
200 µl |
EUR 450 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415391-200l |
Abbexa |
200 µl |
EUR 400 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415790-200l |
Abbexa |
200 µl |
EUR 325 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415793-200l |
Abbexa |
200 µl |
EUR 400 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx415798-200l |
Abbexa |
200 µl |
EUR 450 |
Lambda Light Chain (Lambda-IgLC) Antibody |
abx411151-200g |
Abbexa |
200 µg |
EUR 437.5 |
Ig lambda Light Chain Antibody |
20-abx137078 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Lambda Light Chain Antibody (PE) |
abx140282-100g |
Abbexa |
100 µg |
EUR 400 |
Lambda Light Chain Antibody (HRP) |
GWB-40BCEB |
GenWay Biotech |
1 ml |
Ask for price |
Rat Lambda Light Chain Antibody |
GWB-A1AC1E |
GenWay Biotech |
0.25 mg |
Ask for price |
Lambda Light Chain Antibody (RPE) |
GWB-7AFB60 |
GenWay Biotech |
100 TESTS |
Ask for price |
Lambda Light Chain Antibody (HRP) |
GWB-F5CFB9 |
GenWay Biotech |
1 ml |
Ask for price |
Lambda Light Chain Antibody (RPE) |
GWB-EC7562 |
GenWay Biotech |
0.5 mg |
Ask for price |
Lambda Light Chain Antibody (RPE) |
GWB-C2965F |
GenWay Biotech |
0.5 ml |
Ask for price |
IgG Lambda Light Chain Antibody |
abx240241-100l |
Abbexa |
100 µl |
Ask for price |
IgG Lambda Light Chain Antibody |
abx240241-50l |
Abbexa |
50 µl |
EUR 350 |
Free lambda Light Chain Antibody |
abx023820-1mg |
Abbexa |
1 mg |
EUR 718.8 |
|
Lambda Light Chain Antibody (FITC) |
GWB-3C7F7A |
GenWay Biotech |
0.5 mg |
Ask for price |
lambda Light chain Antibody (FITC) |
GWB-6335F0 |
GenWay Biotech |
0.5 ml |
Ask for price |
Lambda Light Chain Antibody (FITC) |
GWB-Q00609 |
GenWay Biotech |
0.7 mg |
Ask for price |
Lambda Light Chain Antibody (FITC) |
GWB-94C19E |
GenWay Biotech |
1 mg |
Ask for price |
Lambda Light Chain Antibody (FITC) |
GWB-A8D170 |
GenWay Biotech |
0.1 mg |
Ask for price |
Lambda Light Chain Antibody (FITC) |
GWB-DB5C00 |
GenWay Biotech |
1 mg |
Ask for price |
Free lambda Light Chain Antibody |
abx023820-400l |
Abbexa |
400 µl |
EUR 2662.5 |
Free lambda Light Chain Antibody |
abx023820-80l |
Abbexa |
80 µl |
EUR 662.5 |
Sheep Lambda Light Chain Antibody |
GWB-A74A57 |
GenWay Biotech |
2 ml |
Ask for price |
Mouse Lambda Light Chain Antibody |
GWB-6DD727 |
GenWay Biotech |
1 mg |
Ask for price |
Human Lambda Light Chain Antibody |
MBS569684-10mL |
MyBiosource |
10mL |
EUR 365 |
Human Lambda Light Chain Antibody |
MBS569684-5x10mL |
MyBiosource |
5x10mL |
EUR 1455 |
Lambda Light Chain (Lambda-IgLC) Antibody (AP) |
abx411154-1ml |
Abbexa |
1 ml |
EUR 678 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (PE) |
abx413206-200l |
Abbexa |
200 µl |
EUR 475 |
Lambda Light Chain (Lambda-IgLC) Antibody (PE) |
abx415796-200l |
Abbexa |
200 µl |
EUR 525 |
Lambda Light Chain (Lambda-IgLC) Antibody (PE) |
abx411223-100g |
Abbexa |
100 µg |
Ask for price |
Lambda Light Chain (Lambda-IgLC) Antibody (PE) |
abx411223-500g |
Abbexa |
500 µg |
Ask for price |
Lambda Light Chain (Lambda-IgLC) Antibody (PE) |
abx411223-50g |
Abbexa |
50 µg |
EUR 662.5 |
Rabbit Lambda light chain antibody |
70R-10680 |
Fitzgerald |
1 ml |
EUR 368 |
|
Description: Rabbit polyclonal Lambda light chain antibody |
Lambda Light Chain Antibody (Biotin) |
GWB-4C1234 |
GenWay Biotech |
1 mg |
Ask for price |
|
Rabbit Lambda light chain antibody |
MBS837632-1mL |
MyBiosource |
1mL |
EUR 630 |
Rabbit Lambda light chain antibody |
MBS837632-5x1mL |
MyBiosource |
5x1mL |
EUR 2690 |
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx411155-1ml |
Abbexa |
1 ml |
EUR 594 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (RPE) |
abx411223-05mg |
Abbexa |
0.5 mg |
EUR 927.6 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (RPE) |
abx413206-100tests |
Abbexa |
100 tests |
EUR 710.4 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx414084-025mg |
Abbexa |
0.25 mg |
EUR 710.4 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx415792-1ml |
Abbexa |
1 ml |
EUR 594 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx415795-1ml |
Abbexa |
1 ml |
EUR 594 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (RPE) |
abx415796-05ml |
Abbexa |
0.5 ml |
EUR 760.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx414084-200l |
Abbexa |
200 µl |
EUR 487.5 |
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx415792-200l |
Abbexa |
200 µl |
EUR 387.5 |
Lambda Light Chain (Lambda-IgLC) Antibody (ALP) |
abx411154-200g |
Abbexa |
200 µg |
EUR 462.5 |
Lambda Light Chain (Lambda-IgLC) Antibody (HRP) |
abx411155-100g |
Abbexa |
100 µg |
EUR 425 |
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx411152-1mg |
Abbexa |
1 mg |
EUR 811.2 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx413205-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx415791-1mg |
Abbexa |
1 mg |
EUR 560.4 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx415794-05mg |
Abbexa |
0.5 mg |
EUR 526.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx413205-200l |
Abbexa |
200 µl |
EUR 400 |
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx415791-200l |
Abbexa |
200 µl |
EUR 362.5 |
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx415794-200l |
Abbexa |
200 µl |
EUR 350 |
Lambda Light Chain (Lambda-IgLC) Antibody (FITC) |
abx411152-200g |
Abbexa |
200 µg |
EUR 562.5 |
Lambda Light Chain (Lambda-IgLC) Antibody (TRITC) |
abx411153-05mg |
Abbexa |
0.5 mg |
EUR 526.8 |
|
Lambda Light Chain (Lambda-IgLC) Antibody (TRITC) |
abx411220-1mg |
Abbexa |
1 mg |
EUR 560.4 |
|
We show that the acoustic intensities required to provoke inertial cavitation can all be achieved with present medical ultrasound programs. Cell viability and haemolysis research present that nanodroplets are biosuitable. Our outcomes show the good potential of PDA nanodroplets as an acoustically lively nanodevice, which is very priceless for biomedical functions together with drug supply and remedy monitoring.
Welcome to our blog!